Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of Sunday, August 23, 2026.
Forward PE Ratio (N/A) = Close Price ($33.78) / Consensus Forward EPS ($-0.48)
FORWARD PE RATIO
N/A
Hims & Hers Health, Inc.
Market Cap
$7.54B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Hims & Hers Health, Inc. (HIMS) | $7.54B | N/A |
| Oscar Health, Inc. (OSCR)vs › | $8.31B | 18.58 |
| Henry Schein, Inc. (HSIC)vs › | $10.08B | 16.44 |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $10.23B | 39.42 |
| Insulet Corp. (PODD)vs › | $10.26B | 22.78 |
| Molina Healthcare, Inc. (MOH)vs › | $10.46B | N/A |
| Universal Health Services, Inc. (UHS)vs › | $10.73B | 7.85 |
| DaVita Inc. (DVA)vs › | $11.16B | 11.71 |
| Bio-Techne Corporation (TECH)vs › | $11.32B | 37.61 |
| Align Technology, Inc. (ALGN)vs › | $11.64B | 14.40 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus next-FY EPS
At today's $33.78 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.48 | $-0.75 – $-0.09 | 8 | n/m |
| 2027-12-31 | $0.36 | $0.28 – $0.45 | 9 | 93.2x |
| 2028-12-31 | $0.81 | $0.58 – $1.19 | 6 | 41.5x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
